First Report of Klebsiella pneumoniae-Carbapenemase-3-Producing Escherichia coli ST479 in Poland

BioMed Research International
Dominika OjdanaElżbieta Tryniszewska

Abstract

An increase in the antibiotic resistance among members of the Enterobacteriaceae family has been observed worldwide. Multidrug-resistant Gram-negative rods are increasingly reported. The treatment of infections caused by Escherichia coli and other Enterobacteriaceae has become an important clinical problem associated with reduced therapeutic possibilities. Antimicrobial carbapenems are considered the last line of defense against multidrug-resistant Gram-negative bacteria. Unfortunately, an increase of carbapenem resistance due to the production of Klebsiella pneumoniae carbapenemase (KPC) enzymes has been observed. In this study we describe the ability of E. coli to produce carbapenemase enzymes based on the results of the combination disc assay with boronic acid performed according to guidelines established by the European Community on Antimicrobial Susceptibility Testing (EUCAST) and the biochemical Carba NP test. Moreover, we evaluated the presence of genes responsible for the production of carbapenemases (bla KPC, bla VIM, bla IMP, bla OXA-48) and genes encoding other β-lactamases (bla SHV, bla TEM, bla CTX-M) among E. coli isolate. The tested isolate of E. coli that possessed the bla KPC-3 and bla TEM-34 genes was identifi...Continue Reading

References

Aug 19, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Robert GaynesUNKNOWN National Nosocomial Infections Surveillance System
Dec 23, 2006·The Journal of Antimicrobial Chemotherapy·Matthew J EllingtonNeil Woodford
Mar 28, 2009·The Lancet Infectious Diseases·Patrice NordmannThierry Naas
Oct 18, 2011·Emerging Infectious Diseases·Patrice NordmannLaurent Poirel
Apr 18, 2012·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·R CantónUNKNOWN European Network on Carbapenemases
Aug 31, 2012·Emerging Infectious Diseases·Patrice NordmannLaurent Dortet
Dec 24, 2013·Médecine et maladies infectieuses·P Nordmann
Mar 4, 2014·The Journal of Antimicrobial Chemotherapy·Nerea Porres-OsanteYolanda Sáenz

❮ Previous
Next ❯

Citations

Jul 12, 2019·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Dominika OjdanaElżbieta Tryniszewska
May 24, 2019·Folia Microbiologica·Dominika OjdanaElżbieta Tryniszewska

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
PCRs

Related Concepts

Related Feeds

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.